Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasms

Hyperactivation of the Janus kinase 2 (JAK2) signaling pathway leads to myeloproliferative neoplasms (MPNs) and targeting JAK2 can be used as an effective strategy for the treatment of MPNs. Here, our study indicated that WWQ-131 was a highly selective JAK2 inhibitor (IC50 =2.36 nM), with 182-fold a...

Full description

Saved in:
Bibliographic Details
Published inBiomedicine & pharmacotherapy Vol. 156; p. 113884
Main Authors Ge, Huan, Wang, Caolin, Tian, Chaoquan, Diao, Yanyan, Wang, Wanqi, Ma, Xiangyu, Zhang, Jian, Li, Honglin, Zhao, Zhenjiang, Zhu, Lili
Format Journal Article
LanguageEnglish
Published Elsevier Masson SAS 01.12.2022
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Hyperactivation of the Janus kinase 2 (JAK2) signaling pathway leads to myeloproliferative neoplasms (MPNs) and targeting JAK2 can be used as an effective strategy for the treatment of MPNs. Here, our study indicated that WWQ-131 was a highly selective JAK2 inhibitor (IC50 =2.36 nM), with 182-fold and 171-fold more selective to JAK1 and JAK3, respectively. In JAK2V617F-dependent cell lines, WWQ-131 efficaciously inhibited cell proliferation, induced cell cycle arrest at the G2/M phase and apoptosis, and blocked the aberrant activation of JAK2 signaling pathway. In a mouse Ba/F3_JAK2V617F driven disease model, WWQ-131 effectively suppressed STAT5 phosphorylation in spleen and liver, and inhibited Ba/F3_JAK2V617F cells spreading and proliferation in vivo. In addition, WWQ-131 suppressed rhEPO-induced extramedullary erythropoiesis and polycythemia in mice, as well as hematocrits and spleen sizes, especially had no effect on white blood cell count. Furthermore, WWQ-131 (75 mg/kg) exhibited stronger therapeutic effects than fedratinib (120 mg/kg) in these two MPN models. Taken together, this study suggests that WWQ-131 will be a promising candidate for the treatment of MPNs. [Display omitted] •WWQ-131 was identified as a potent and highly selective inhibitor of JAK2.•WWQ-131 blocked the aberrant activation of JAK2-mediated signaling pathway.•WWQ-131 suppressed tumor cells proliferation in a Ba/F3_JAK2V617F xenograft model.•WWQ-131 suppressed rhEPO-induced polycythemia in mice.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0753-3322
1950-6007
DOI:10.1016/j.biopha.2022.113884